전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,092 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Preclinical

T cell injection targeting CD19 chimeric antigen receptor (T cell injection targeting CD19 chimeric antigen receptor)

Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathies · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 30Status Active
AntibodyLimited DatastaleTG Therapeutics, Inc.Phase 2

Ublituximab (Ublituximab)

Non-Hodgkins Lymphoma; B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase2#monoclonal-antibody#Non-HodgkinsLymphoma+2
Trials 30Status Active
CGTLimited DatastaleKara Yakhteh Tajhiz Azma CompanyPhase 2

anti-CD19 CAR T cell therapy (anti-CD19 CAR T cell therapy)

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleHrain Biotechnology Co., Ltd.Preclinical

anti-CD19-CAR vector-transduced T cells (anti-CD19-CAR vector-transduced T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 30Status Active
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Preclinical

chimeric antigen receptor gene modified T cells (chimeric antigen receptor gene modified T cells)

Lymphoma, B-Cell · CD30

#CD30#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleGlycostem Therapeutics BVPhase 1

umbilical cord blood NK cells (umbilical cord blood NK cells)

Neuroblastoma · Soft Tissue Sarcoma (STS)

#SoftTissueSarcomaSTS#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

Toripalimab + cetuximab (3cycles, 3cycles (Toripalimab + cetuximab))

Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#NeoadjuvantTherapy+1
Trials 29Status Recruiting
AntibodyLimited DatastaleAbbViePhase 3

Budigalimab (Budigalimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 29Status Recruiting
AntibodyLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#LargeB-cellLymphoma+2
Trials 29Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Group Co.…Phase 1

Fast CAR T cells (Fast CAR T cells)

Solid Tumor · Solid Tumor

#SolidTumor#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 28Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

Oleclumab (Oleclumab)

Non-small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancer+1
Trials 28Status Recruiting
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Phase 1

anti-CD19/CD22 CAR-T cells (anti-CD19/CD22 CAR-T cells)

MRD-positive; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 28Status Active
CGTLimited DatastaleGracell Biotechnology Ltd.Phase 1

BCMA/CD19 Dual-Target CAR-T (BCMA/CD19 Dual-Target CAR-T)

Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 27Status Active
CGTLimited DatastaleDompé Farmaceutici S.p.APhase 1

Ex-Vivo expanded autologous IL-8 receptor (CXCR2, Ex-Vivo expanded autologous IL-8 receptor, Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells)

Brain Metastases · Glioblastoma Multiforme

#GlioblastomaMultiforme#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 25Status Recruiting
CGTLimited DatastaleNkarta, Inc.Phase 2

allogeneic, donor-derived NK cells (allogeneic, donor-derived NK cells)

Acute Myelogenous Leukemia · Acute Myelogenous Leukemia

#AcuteMyelogenousLeukemia#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 25Status Discontinued
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#antibody-drug-conjugate#RefractoryPeripheralT-CellLympho+2
Trials 24Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

Breast Cancer (Advanced/Metastatic); HER2-positive Breast Cancer · Malignant Glioma

#MalignantGlioma#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 23Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

Necitumumab (Necitumumab)

Squamous Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SquamousCellCarcinoma+1
Trials 23Status Discontinued
CGTLimited DatastaleUTC Therapeutics Inc.Phase 1

anti-mesothelin CAR-T cells (anti-mesothelin CAR-T cells)

Solid Tumor, Adult · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 23Status Recruiting
AntibodyLimited DatastalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#monoclonal-antibody#Carcinoma+3
Trials 23Status Discontinued

8 / 55 pages

← PreviousNext →